A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationJohn T. Brandt, Kenneth J. Winters, Christopher D. Payne et al.|American Heart Journal|2006Cited by 571
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseTomas Jernberg, Lars Wallentin, Christopher D. Payne et al.|European Heart Journal|2006Cited by 537
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics DifferentlyNazar Farid, Daniel E. Salazar, Christopher D. Payne et al.|Clinical Pharmacology & Therapeutics|2007Cited by 323
Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex VivoDavid Erlinge, Lars Wallentin, Christoph Varenhorst et al.|Journal of the American College of Cardiology|2008Cited by 216
Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose ClopidogrelChristopher D. Payne, Kenneth J. Winters, Daniel E. Salazar et al.|Journal of Cardiovascular Pharmacology|2007Cited by 167